ivermectin   Click here for help

GtoPdb Ligand ID: 2373

Synonyms: Heartgard® | ivermectin B1a | MK-933 | Sklice® | Soolantra®
Approved drug
ivermectin is an approved drug (FDA (1996), UK (2015))
Compound class: Synthetic organic
Comment: Ivermectin is a broad-spectrum anti-parasitic drug. The approved drug is a mixture of mainly avermectin H2B1a (CAS # 71827-03-7) with some avermectin H2B1b (CAS # 70209-81-3). The avermectins are bacterial marcrolides isolated from Streptomyces avermitilis.

SARS-CoV-2 and COVID-19: There is speculation that ivermectin could be used to treat COVID-19, which is principally founded on in vitro evidence of anti-viral activity, and limited evidence of anti-inflammatory action. The evidence that ivermectin is appropriate to prevent or treat coronavirus infection is not compelling. To date (Jan 2021) there is no persuasive efficacy data available from an adequately sized, appropriately designed and controlled randomised clinical trial.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 14
Hydrogen bond donors 3
Rotatable bonds 8
Topological polar surface area 170.06
Molecular weight 874.51
XLogP 2.84
No. Lipinski's rules broken 1
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES COC1CC(OC2C(C)C=CC=C3COC4C3(O)C(C=C(C4O)C)C(=O)OC3CC(CC=C2C)OC2(C3)CCC(C(O2)C(CC)C)C)OC(C1OC1CC(OC)C(C(O1)C)O)C
Isomeric SMILES CO[C@H]1C[C@H](OC2C(C)/C=C/C=C/3\COC4C3(O)[C@@H](C=C([C@H]4O)C)C(=O)O[C@H]3CC(C/C=C/2\C)O[C@]2(C3)CCC(C(O2)C(CC)C)C)O[C@H](C1O[C@H]1C[C@H](OC)C([C@@H](O1)C)O)C
InChI InChI=1S/C48H74O14/c1-11-25(2)43-28(5)17-18-47(62-43)23-34-20-33(61-47)16-15-27(4)42(26(3)13-12-14-32-24-55-45-40(49)29(6)19-35(46(51)58-34)48(32,45)52)59-39-22-37(54-10)44(31(8)57-39)60-38-21-36(53-9)41(50)30(7)56-38/h12-15,19,25-26,28,30-31,33-45,49-50,52H,11,16-18,20-24H2,1-10H3/b13-12+,27-15+,32-14+/t25?,26?,28?,30-,31-,33?,34-,35-,36-,37-,38-,39-,40+,41?,42?,43?,44?,45?,47+,48?/m0/s1
InChI Key AZSNMRSAGSSBNP-ZLRQRZFZSA-N
References
1. Khakh BS, Proctor WR, Dunwiddie TV, Labarca C, Lester HA. (1999)
Allosteric control of gating and kinetics at P2X(4) receptor channels.
J Neurosci, 19 (17): 7289-99. [PMID:10460235]
2. Krause RM, Buisson B, Bertrand S, Corringer PJ, Galzi JL, Changeux JP, Bertrand D. (1998)
Ivermectin: a positive allosteric effector of the alpha7 neuronal nicotinic acetylcholine receptor.
Mol Pharmacol, 53 (2): 283-94. [PMID:9463487]
3. Nörenberg W, Sobottka H, Hempel C, Plötz T, Fischer W, Schmalzing G, Schaefer M. (2012)
Positive allosteric modulation by ivermectin of human but not murine P2X7 receptors.
Br J Pharmacol, 167 (1): 48-66. [PMID:22506590]
4. Shan Q, Haddrill JL, Lynch JW. (2001)
Ivermectin, an unconventional agonist of the glycine receptor chloride channel.
J Biol Chem, 276 (16): 12556-64. [PMID:11278873]